HPA Axis in the Pathomechanism of Depression and Schizophrenia: New Therapeutic Strategies Based on Its Participation

Autor:	Mariola Herbet, Gabriela Juszczyk, Joanna Mikulska, Monika Gawrońska-Grzywacz
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	endocrine system Neurosciences. Biological psychiatry. Neuropsychiatry Disease Review Gut flora cortisol stress Glucocorticoid receptor medicine Chronic stress Depression (differential diagnoses) biology business.industry General Neuroscience HPA axis medicine.disease biology.organism_classification schizophrenia psychiatric disorders Schizophrenia inflammation Immunology depression Major depressive disorder Bacterial antigen business hormones hormone substitutes and hormone antagonists RC321-571
Zdroj:	Brain Sciences Brain Sciences, Vol 11, Iss 1298, p 1298 (2021)
ISSN:	2076-3425
Popis:	The hypothalamic-pituitary-adrenal (HPA) axis is involved in the pathophysiology of many neuropsychiatric disorders. Increased HPA axis activity can be observed during chronic stress, which plays a key role in the pathophysiology of depression. Overactivity of the HPA axis occurs in major depressive disorder (MDD), leading to cognitive dysfunction and reduced mood. There is also a correlation between the HPA axis activation and gut microbiota, which has a significant impact on the development of MDD. It is believed that the gut microbiota can influence the HPA axis function through the activity of cytokines, prostaglandins, or bacterial antigens of various microbial species. The activity of the HPA axis in schizophrenia varies and depends mainly on the severity of the disease. This review summarizes the involvement of the HPA axis in the pathogenesis of neuropsychiatric disorders, focusing on major depression and schizophrenia, and highlights a possible correlation between these conditions. Although many effective antidepressants are available, a large proportion of patients do not respond to initial treatment. This review also discusses new therapeutic strategies that affect the HPA axis, such as glucocorticoid receptor (GR) antagonists, vasopressin V1B receptor antagonists and non-psychoactive CB1 receptor agonists in depression and/or schizophrenia.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f7698d48da67352dfe4d8b40449c3e7 http://europepmc.org/articles/PMC8533829 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.